Cutanix DRL (Quadrinone) reduces redness

Written by on October 6, 2005 in cutanix, Red Face of Rosacea, Rosacea Topicals with 3 Comments

BioForm Medical, the owners of Cutanix Corporation, have announced that Quadrinone, the active ingredient in their products, is `4-ethoxybenzaldehyde’. Quadrinone is known to many in the rosacea community via the products known as Dramatic Relief Multi-Action Skin Therapy or (DRL).

This announcement accompanies the paper entitled The Efficacy of 1% 4-ethoxybenzaldehyde (Quadrinone) in Reducing Facial Erythema, where the effects of DRL were examined in a pilot study of 30 people with mild to moderate facial rosacea. Twenty of the study subjects were randomly selected to receive the DRL, which they applied to their face twice daily, while the other 10 subjects in the control group only received the lotion vehicle – without Quadrinone.

Dr. Draelos reported “that there was a statistically significant improvement in erythema (facial redness), uneven skin tone, desquamation (peeling) and overall severity of rosacea.”

Related Articles

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed

3 Reader Comments

  1. Erin says:

    I loved Cutanix. Is anybody making a product that utilizes Quadrinone anymore?

  2. sophie says:

    You can get the same stuff at Skin actives and mix with their canvas base

    I use to use cutanix too – and this has been a great substitute (and cheaper)

Leave your comment here


Discover more from Rosacea Support Group

Subscribe now to keep reading and get access to the full archive.

Continue reading

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.